- Home
- RMNI vs IMMP Comparison
RMNI vs IMMP Comparison
Compare RMNI & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMNI
- IMMP
- Stock Information
- Founded
- RMNI 2005
- IMMP 1987
- Country
- RMNI United States
- IMMP Australia
- Employees
- RMNI N/A
- IMMP N/A
- Industry
- RMNI Business Services
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- RMNI Consumer Discretionary
- IMMP Health Care
- Exchange
- RMNI Nasdaq
- IMMP Nasdaq
- Market Cap
- RMNI 256.4M
- IMMP 304.0M
- IPO Year
- RMNI N/A
- IMMP N/A
- Fundamental
- Price
- RMNI $2.79
- IMMP $1.98
- Analyst Decision
- RMNI Buy
- IMMP Buy
- Analyst Count
- RMNI 2
- IMMP 2
- Target Price
- RMNI $6.00
- IMMP $8.50
- AVG Volume (30 Days)
- RMNI 338.5K
- IMMP 95.6K
- Earning Date
- RMNI 02-26-2025
- IMMP 02-27-2025
- Dividend Yield
- RMNI N/A
- IMMP N/A
- EPS Growth
- RMNI N/A
- IMMP N/A
- EPS
- RMNI N/A
- IMMP N/A
- Revenue
- RMNI $426,650,000.00
- IMMP $2,563,302.00
- Revenue This Year
- RMNI N/A
- IMMP N/A
- Revenue Next Year
- RMNI N/A
- IMMP $47.79
- P/E Ratio
- RMNI N/A
- IMMP N/A
- Revenue Growth
- RMNI N/A
- IMMP 9.59
- 52 Week Low
- RMNI $1.53
- IMMP $1.66
- 52 Week High
- RMNI $3.43
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- RMNI 58.64
- IMMP 46.29
- Support Level
- RMNI $2.73
- IMMP $1.90
- Resistance Level
- RMNI $2.91
- IMMP $2.05
- Average True Range (ATR)
- RMNI 0.16
- IMMP 0.09
- MACD
- RMNI -0.01
- IMMP -0.02
- Stochastic Oscillator
- RMNI 70.24
- IMMP 19.44
About RMNI Rimini Street Inc. (DE)
Rimini Street Inc is a provider of enterprise software support products and services and a third-party support provider for Oracle and SAP software products based in the United States. The company offers solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. Some of its products include Oracle E-business suite, Oracle Database, Peoplesoft, SAP business suite, and others. The company derives maximum revenue from United states.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.